

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 33/36	A1	(11) International Publication Number: WO 99/55344 (43) International Publication Date: 4 November 1999 (04.11.99)
(21) International Application Number: PCT/CN98/00118 (22) International Filing Date: 6 July 1998 (06.07.98) (30) Priority Data: 98 1 01635.9 24 April 1998 (24.04.98) CN (71)(72) Applicant and Inventor: LU, Daopei [CN/CN]; Staff Living Quarter, People's Hospital, Beijing Medical University, 42 Bei Li Shi Lu, Beijing 100044 (CN). (74) Agent: CHINA PATENT AGENT (H.K.) LTD.; 22/F, Great Eagle Centre, 23 Harbour Road, Wanchai, Hong Kong; Special Administrative Region (CN).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: ARSENIC SULFIDE COMPOUNDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF MALIGNANCIES (57) Abstract The present invention relates to arsenic sulfide compounds. The present invention also relates to pharmaceutical compositions useful for treating cancer, such as leukemia or lymphoma, which comprises an arsenic sulfide compound. The present invention further relates to methods for treating cancer, such as leukemia or lymphoma, using an arsenic sulfide compound. Finally, the present invention relates to processes for producing arsenic disulfide (As ₂ S ₄).		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**ARSENIC SULFIDE COMPOUNDS AND DERIVATIVES THEREOF
FOR THE TREATMENT OF MALIGNANCIES**

5

1. FIELD OF INVENTION

The present invention relates to arsenic sulfide compounds. The present invention also relates to pharmaceutical compositions useful for treating cancer, preferably hematological cancer and more preferably leukemia or lymphoma, which comprise an arsenic sulfide compound. The present invention further relates to methods for treating cancer, preferably hematological cancer and more preferably leukemia or lymphoma, using an arsenic sulfide compound. Finally, the present invention relates to processes for producing arsenic disulfide (As_2S_3).

10

15

2. BACKGROUND OF THE INVENTION

2.1. CANCER

Cancer is characterized primarily by an increase in the number of abnormal cells derived from a given normal tissue, invasion of adjacent tissues by these abnormal cells, and lymphatic or blood-borne spread of malignant cells to regional lymph nodes and to distant sites (metastasis). Clinical data and molecular biologic studies indicate that cancer is a multistep process that begins with minor preneoplastic changes, which may under certain conditions progress to neoplasia.

25

Leukemia refers to malignant neoplasms of the blood-forming tissues. Transformation to malignancy typically occurs in a single cell through two or more steps with subsequent proliferation and clonal expansion. In some leukemias, specific chromosomal translocations have been identified with consistent leukemic cell morphology and special clinical features (e.g., translocations of 9 and 22 in chronic myelocytic leukemia, and of 15 and 17 in acute promyelocytic leukemia). Acute leukemias are predominantly undifferentiated cell populations and chronic leukemias more mature cell forms.

30

35

Acute leukemias are divided into lymphoblastic (ALL) and non-lymphoblastic (ANLL or AML) types. They may be further

40

SUBSTITUTE SHEET (RULE 26)

subdivided by their morphologic and cytochemical appearance according to the French-American-British (FAB) classification or according to their type and degree of differentiation. The use of specific B- and T-cell and myeloid-antigen monoclonal antibodies are most helpful for classification. ALL is predominantly a childhood disease which is established by laboratory findings and bone marrow examination. ANLL or AML occurs at all ages and is the more common acute leukemia among adults; it is the form usually associated with irradiation as a causative agent.

One type of acute leukemias, acute promyelocytic leukemia (APL) is associated with the t(15;17) translocation, which generates a PML/RAR α fusion protein between PML, a growth suppressor localized on nuclear matrix-associated bodies, and RAR α , a nuclear receptor for retinoic acid (RA). PML/RAR α was proposed to block myeloid differentiation through inhibition of nuclear receptor response, as does a dominant negative RAR α mutant. In addition, in APL cells, PML/RAR α displaces PML and other nuclear body (NB) antigens onto nuclear microspeckles, likely resulting in the loss of PML and/or NB functions. Diagnosis of acute promyelocytic leukemia (APL) is indicated most importantly on the morphological feature of APL cells in blood and bone marrow. A chromosomal translocation, t(15;17) is also typical of APL and is shown by banding or fluorescence in situ hybridization (FISH) staining techniques. The translocation can often be discovered in patients with APL, especially prior to complete remission. Polymerase chain reaction (PCR) of the patient's marrow also shows PML/RAR α mRNA. Additionally, certain immunological markers, such as CD33 $^{+}$, CD13 $^{+}$, CD9 $^{+}$ CD34 $^{-}$ and HLA-DR $^{-}$, are predominantly present in marrow cells.

Chronic leukemias are described as being lymphocytic (CLL) or myelocytic (CML). CLL is characterized by the appearance of mature lymphocytes in blood, bone marrow, and lymphoid organs. The hallmark of CLL is sustained, absolute lymphocytosis ($> 5,000/\mu\text{L}$) and an increase of lymphocytes in the bone marrow. Most CLL patients also have clonal expansion of lymphocytes with B-cell characteristics. CLL is

a disease of older persons. In CML (chronic myelocytic leukemia or chronic myeloid leukemia), the characteristic feature is the predominance of granulocytic cells of all stages of differentiation in blood, bone marrow, liver, spleen, and other organs. In the symptomatic patient at diagnosis the total WBC count is usually about 200,000/ μ L, but may reach 1,000,000/ μ L. CML is relatively easy to diagnose because of the presence of the Philadelphia chromosome.

With an incidence of 59,000 cases a year, the malignant lymphomas collectively represent the sixth most common causes of cancer in the United States. They are a heterogeneous group of disorders; about 15% of patients with malignant lymphomas have Hodgkin's disease, and the remainder have one of the non-Hodgkin's lymphomas. The etiology, epidemiology, pathology, clinical features, diagnostic evaluation and staging, treatment and management of lymphomas are disclosed in Malignant Lymphomas, the content of which is incorporated herein by reference. CML has been classified according to clinical courses such as, high grade, intermediate grade or low grade CML. Alternatively, CML has been classified according to immunological phenotyping such as T-cell, B-cell, or cytogenetic (chromosomal) aberrations. Histopathological changes and morphological changes are very important in the classification of CML. According to the current classification system, the non-Hodgkin's lymphomas are further subdivided into follicular, small cleaved cell and follicular, mixed small cleaved and large cell lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, mucosa-associated lymphoid tissue lymphoma, monocytoid B cell lymphomas, follicular, large cell lymphoma, diffuse, small cleaved cell lymphoma, diffuse, mixed small cleaved and large cell lymphoma, diffuse, large cell lymphoma, immunoblastic lymphoma, thymic B cell lymphoma, diffuse, small noncleaved cell lymphoma, lymphoblastic lymphoma, peripheral T cell lymphoma, large cell anaplastic lymphoma and non-Hodgkin's lymphomas in acquired immunodeficiency syndrome.

The very nature of hematopoietic cancer necessitates using systemic chemotherapy as the primary treatment modality. Drugs selected according to sensitivities of specific leukemias and lymphomas are usually given in combination. Radiation therapy may be used as an adjunct to treat local accumulations of leukemic cells. Surgery is rarely indicated as a primary treatment modality, but may be used in managing some complications. Bone marrow transplantation from an HLA-matched sibling is sometimes indicated.

2.2. ARSENIC AND ITS MEDICAL USES

Arsenic has been considered to be both a poison and a drug for a long time in both Western and Chinese medical practices. In the latter part of the nineteenth century, arsenic was used frequently in attempts to treat diseases of the blood in the West. In 1878, it was reported that treatment of a leukemic patient with Fowler's solution (a solution containing potassium arsenite, valence +5) reduced markedly the count of white blood cells (Cutler and Bradford, Am. J. Med. Sci., January 1878, 81-84). Further interests in the use of Fowler's solution as a palliative agent to treat chronic myelogenous leukemia (CML) was described by Forkner and Scott in 1931 (J. Am. Med. Assoc., 1931, iii, 97), and later confirmed by Stephens and Lawrence in 1936 (Ann. Intern. Med. 9, 1488-1502). However, while the active chemical ingredient(s) of Fowler's solution was not determined, its toxicity was well recognized. Fowler's solution was administered strictly as an oral composition, and was given to leukemic patients as a solution until the level of white blood cells was depressed to an acceptable level or until toxicities (such as skin keratoses and hyperpigmentation) developed, while the patients enjoyed varying periods of remission. In the 1960's, Fowler's solution was still used occasionally in attempts to treat CML, however, most patients with CML were treated with other chemotherapeutic agents, such as busulfan, and/or radiation therapy (Monfardini et al., Cancer, 1973, 31:492-501). JP

51-88,620 discloses a process which involves crushing and oxidizing Fe, As and FeS, stirring in water, allowing to stand, and collecting the resulting supernatant containing ferrous, arsenic and sulphate ions, followed by filtration.

5 JP 51-88,620 also discloses that the product of the above process can cure cancerous disease of stomach, duodenum, uterus, lung, pancreas etc.; and is effective in treating diabetes mellitus, heart disease, hypertension, asthma, neuralgia, rheumatism, etc.

10 Paradoxically, one of the long recognized effects of exposure to arsenic, whether the source is environmental or medicinal, is skin cancer (Hutchinson, 1888, Trans. Path. Soc. Lond., 39:352; Neubauer, 1947, Br. J. Cancer, 1:192). There were even epidemiological data to suggest that the use
15 of Fowler's solution over long periods could lead to an increased incidence of cancer at internal sites (Cuzick et al., Br. J. Cancer, 1982, 45:904-911; Kaspar et al., J. Am. Med. Assoc., 1984, 252:3407-3408). The carcinogenicity of arsenic has since been demonstrated by the fact that it can
20 induce chromosomal aberration, gene amplification, sister chromatid exchanges and cellular transformation (See e.g., Lee et al., 1988, Science, 241:79-81; and Germolec et al., Toxicol. Applied Pharmacol., 1996, 141:308-318). In a mass
25 screening for cancer in the realgar and tin mines, certain epidemical characteristics were found in precancerous lesion of lung cancer (Wang, Chung Hua Chung Liu Tsa Chih, 1989, 11(3):207-210). Fershagen and Bjorklund, Cancer Lett., 1985, 27(1):99-104, showed that calcium arsenate is tumorigenic, while evidence is inconclusive for arsenic trisulfide (See
30 also Yamamoto et al., Int. J. Cancer, 1987, 40(2):220-223). EPA/600/8-91/061 (OHEA-C-073-005) reports that arsenic and inorganic arsenic compounds, including, *inter alia*, arsenic disulfide and arsenic trisulfide, are human carcinogens. It
35 further discloses that "since arsenic compounds are chemically convertible to the carcinogenic form(s) both in vitro and in vivo, and the exact species of inorganic arsenic that is directly carcinogenic in humans is not known, all the above inorganic arsenic compounds are of equal concern."

Because of the known carcinogenic effect of arsenic, its only therapeutic use in human in Western medicine today is in the treatment of tropical diseases, such as African trypanosomiasis, (the organic arsenical, melarsoprol; See Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th edition, chapter 66, 1659-1662, 1997).

In traditional Chinese medicine, arsenous acid or arsenic trioxide paste has been used to treat tooth marrow diseases, psoriasis, syphilis and rheumatosis (Chen et al., 1995, in *Manual of Clinical Drugs*, Shanghai, China, Shanghai Institute of Science and Technology, p.830). In 1970's, arsenic trioxide had been applied experimentally to treat acute promyelocytic leukemia (APL) in China (commented by Mervis, 1996, *Science*, 273:578). The clinical efficacy of arsenic trioxide has recently been re-investigated in 14 of 15 patients with refractory APL, where the use of an intravenous dose at 10 mg/day for 4-9 weeks was reported to result in complete morphologic remission without associated bone marrow suppression (Shen et al., 1997, *Blood*, 89:3354-3360). It was also shown that arsenic trioxide induced apoptosis (programmed cell death) in vitro in NB4 cells, an APL cell line, and that apoptosis was apparently associated with down-regulation of the oncogene bcl-2, and intracellular redistribution of the chimeric PML/RAR α protein that are unique to APL cells (Chen et al., 1996, *Blood*, 88:1052-1061; Andre et al., 1996, *Exp. Cell Res.* 229:253-260). It has been reported that the biological activity of arsenic is due to the ability of arsenic to direct the nucleoplasmic fraction of PML to nuclear bodies for degradation (Zhu et al., 1997, *Proc. Natl. Acad. Sci.*, 94:3978-3983).

Realgar (Xiong-Huang), an ore crystal containing mainly arsenic disulfide, has been popular in China for hundreds of years as a drug in traditional medicine and for keeping out the malign among laymen. CN 1,133,725 discloses that an exterior-use plaster which is prepared from 26 Chinese medicinal materials, including inter alia, realgar, can be used in treating liver cancer. CN 1,131,037 discloses that a new anti-carcinogen, suitable for curing exposure carcinosis,

can be prepared from 21 Chinese medicinal materials, including *inter alia*, realgar. CN 1,122,700 discloses that a medicinal powder, comprising garcinia, realgar, frankincense, myrrh, artemisia, rupestris, rosin, vomiting nut and alum, can be used to treat mastosis, mammary tuberculosis sore and tumor. CN 1,119,113 discloses that a compound capsule comprising 24 Chinese medicinal materials, including *inter alia*, realgar, can be used in preventing and treating various cancers. CN 1,081,104 discloses that a plaster, which is produced from a variety of Chinese medicinal materials, including *inter alia*, red orpiment (a material similar to realgar), has long-term analgesic effect, especially for soothing cancer pain. CN 1,061,908 discloses that a composition produced from white arsenic, alum, realgar and myrrh can be used to treat cancer.

Although realgar has been used as one component to form a composition that has been indicted useful in treating or preventing various forms of cancer, realgar alone has never been suggested or used to treat cancer, especially leukemias or lymphomas. In addition, arsenic sulfide compound, whether alone or in combination, has never been suggested or used to treat any forms of cancer, including leukemias or lymphomas. On the contrary, there is concern in the medical field that realgar, or certain arsenic sulfide compounds, such as arsenic disulfide and arsenic trisulfide, are human carcinogens.

Qi and Bi, Chung Yao Tung Pao, 1983, 8(5):21 discloses a method of removing As_2O_3 from realgar ore using 1% HCl solution. Yuan et al., Chung Yao Tung Pao, 1988, 13(8):17-21 discloses that treating realgar ore with HCl or vinegar can reduce As_2O_3 content in the realgar ore. Yuan et al., Chung Yao Tung Pao, 1988, 13(8):17-21 also discloses that besides As_4S_4 and As_2O_3 , realgar contains more than 10 other trace elements, and since the efficacy of realgar depends on all those trace elements, it is a concern that washing realgar with HCl will remove most of the trace elements. Zhang et al., Zhongguo Zhongyao Zaohi, 1995, 20(9):537 discloses that

treating realgar ore with yogurt (acidic milk) can reduce realgar's toxicity.

5 There is a great need for effective treatments of cancer, particularly hematological cancer including leukemias and lymphomas. Further, there is a great need for orally active anticancer agents. The present invention addresses these and other needs in the art.

3. SUMMARY OF THE INVENTION

10 Despite reports concerning the risks associated with the administration of arsenic sulfide compound to patients, applicant has discovered surprisingly that certain arsenic sulfide compounds have broad applicability in the treatment of various types of cancers, particularly, hematological
15 cancer including leukemias and lymphomas. The arsenic sulfide compound can be used safely and effectively in mammals. Accordingly, the invention encompasses arsenic sulfide compounds, the preparation of these compounds, their incorporation into pharmaceutical compositions and their use
20 to treat cancer.

The invention described herein encompasses any arsenic sulfide compound, or derivatives thereof, or a mixture with other arsenious compound, that can alleviate, reduce, ameliorate, or prevent cancer; or place or maintain in a
25 state of remission of clinical symptoms or diagnostic markers associated with cancer, particularly hematological cancer including leukemias or lymphomas.

The present invention also encompasses pharmaceutical compositions useful for treating cancer, particularly
30 hematological cancer including leukemia or lymphoma, which comprises an arsenic sulfide compound or realgar, preferably with a pharmaceutically acceptable carrier or excipient. In a preferred embodiment the invention encompasses a composition suitable for oral delivery, comprising one or
35 more arsenic sulfide compounds and a pharmaceutically acceptable carrier or excipient in tablet, capsule, or other single unit dosage form. In another embodiment, the invention includes compositions suitable for topical,

transdermal or parenteral delivery. Specific therapeutic regimens, pharmaceutical compositions, and kits are also provided by the invention.

5 The invention further encompasses a method of treating cancer, particularly hematological cancer including leukemia or lymphoma, comprising the administration of a therapeutically effective and non-lethal amount of an arsenic sulfide compound or realgar, preferably with a pharmaceutically acceptable carrier or excipient, to a human
10 in need of such therapy.

The invention also encompasses the use of combination therapy to treat cancers, especially cancers which are refractory to other forms of treatment. In accordance with the present invention, arsenic sulfide compound can be used
15 alone or in combination with other known therapeutic agents (including chemotherapeutics, radioprotectants and radiotherapeutics) or techniques to either improve the quality of life of the patient, or to treat cancer, particularly hematological cancer such as leukemia or
20 lymphoma. The arsenic sulfide compounds can be used before, during or after the administration of one or more known chemotherapeutic agents. In addition, the arsenic sulfide compounds can be used before, during or after radiation treatment. The most preferred combinational therapy is an
25 arsenic sulfide compound and arsenic trioxide used simultaneously or sequentially.

Finally, the invention encompasses a process for producing arsenic disulfide (As_2S_3) that is substantially free of arsenic trioxide (As_2O_3).

30 Particular compositions of the invention and their uses are described in the sections and subsections which follow.

4. BRIEF DESCRIPTION OF THE DRAWINGS

35 Fig. 1 is a graph showing change of hemoglobin and platelet counts for case study 1 (treatment of a newly-diagnosed APL patient using arsenic disulfide).

Fig. 2 is a graph showing change of blast and white blood cell counts for case study 1 (treatment of a newly-diagnosed APL patient using arsenic disulfide).

5 Fig. 3 is a graph showing change of hemoglobin and platelet counts for case study 2 (treatment of an APL patient in relapsing stage using arsenic disulfide).

Fig. 4 is a graph showing change of blast and white blood cell counts for case study 2 (treatment of an APL patient in relapsing stage using arsenic disulfide).

10

5. DETAILED DESCRIPTION OF THE INVENTION

Compounds, compositions and methods for the treatment of cancer, particularly hematological cancer including leukemia and lymphoma, are described herein.

15

The present invention encompasses pharmaceutical compositions useful for treating cancer, particularly hematological cancer including leukemia or lymphoma, which comprises an arsenic sulfide compound or realgar, preferably with a pharmaceutically acceptable carrier or excipient. In a preferred embodiment the invention encompasses a composition suitable for oral delivery, comprising one or more arsenic sulfide compounds, and preferably a pharmaceutically acceptable excipient or carrier in tablet, capsule, or other single unit dosage form.

20

25

This invention also encompasses a method for treating cancer, particularly hematological cancer including leukemia or lymphoma, in a mammal including humans, which comprises administering to a subject in need of such therapy a therapeutically effective and non-lethal amount of one or more arsenic sulfide compounds, such as arsenic disulfide or arsenic trisulfide, preferably with a pharmaceutically acceptable carrier or excipient.

30

The invention further encompasses the use of combination therapy to treat cancers, especially cancers which are refractory to other forms of treatment. For treating leukemias or lymphomas, the most preferred combinational therapy is an arsenic sulfide compound and an arsenic trioxide used simultaneously or sequentially.

35

Finally, the invention encompasses a process for producing arsenic disulfide (As_2S_4) that is substantially free of arsenic trioxide (As_2O_3).

For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections which follow.

5.1. THE ARSENIC SULFIDE COMPOUNDS

As used herein, "arsenic sulfide compound" refers to, in a pharmaceutically acceptable form, a compound which comprises both arsenic and sulfur. The invention encompasses all pharmaceutically active species of arsenic sulfur, regardless whether such species are organic or inorganic molecules, salts or solution thereof, or mixtures thereof. The term "arsenic sulfide compound" also encompasses hydrated versions, such as aqueous solution, hydrolyzed products or ionized products, of these compounds; and these compound may contain different number of attached water molecules. Any arsenic sulfide compound(s), when used alone or in combination with other compounds, that can alleviate, reduce, ameliorate, prevent, or place or maintain in a state of remission of clinical symptoms or diagnostic markers associated with cancers, particularly hematological cancers including leukemias or lymphomas, can be used in the present invention.

Examples of "arsenic sulfide compound" include, but are not limited to, compounds with the molecular formulae of $(\text{As}_m\text{S}_n)_x$, wherein m, n and x are the same or different and alternate integrals. Examples of such compounds include, but are not limited to, arsenic disulfide (As_2S_4), arsenic pentasulfide (As_2S_5) and arsenic trisulfide (As_2S_3). In certain references, arsenic disulfide, arsenic sulfide or tetra arsenic tetra sulfide (TATS) are used interchangeably as the name of As_2S_4 . For consistency, only "arsenic disulfide" will be used herein in the present application as the name of As_2S_4 . Arsenic disulfide (As_2S_4) can be prepared from realgar according to procedures described in § 5.4. Alternatively, As_2S_4 can be prepared according to the

procedures taught in *Gmelin's Arsenic* (8th Ed.) 17:417-422 (1952), or taught in *Schenk in Handbook of Preparative Inorganic Chemistry* 1:603 (G. Brauer, Ed., Academic press, New York, 2nd Ed. 1963). Arsenic pentasulfide (As_2S_5) can be prepared according to the procedures taught in *Schenk in Handbook of Preparative Inorganic Chemistry* 1:603 (G. Brauer, Ed., Academic press, New York, 2nd Ed. 1963). Arsenic trisulfide (As_2S_3) can be prepared according to the procedures taught in *Gmelin's Arsenic* (8th Ed.) 17:422-433 (1952).

5.2. PHARMACEUTICAL COMPOSITION AND MODES OF ADMINISTRATION

The present invention provides a pharmaceutical composition useful for treating cancer, particularly hematological cancer including leukemia or lymphoma, in a mammal which comprises an effective amount of an arsenic sulfide compound, and preferably a pharmaceutically acceptable carrier or incipient. In a preferred embodiment the invention provides a composition suitable for oral delivery, comprising one or more arsenic sulfide compounds, and preferably a pharmaceutically acceptable carrier or incipient in tablet, capsule, or other single unit dosage form.

In a specific embodiment, the arsenic sulfide compound is selected from the group consisting of As_2S_2 , As_2S_3 , As_2S_5 , and As_4S_4 . Preferably, the arsenic sulfide compound is As_4S_4 . More preferably, the As_4S_4 is produced according to the methods disclosed in § 5.4. Mixtures of these compounds can also be used.

In another specific embodiment, the amount of the arsenic sulfide compound, e.g., As_4S_4 , is from about 100 mg to about 2 g per unit dosage form.

In still another specific embodiment, the pharmaceutically acceptable carrier is a plant semen. Preferably, the plant semen is *seman platycladi*.

In yet another specific embodiment, the arsenic sulfide compound is present in an amount on weight basis, relative to the pharmaceutically acceptable carrier, in about equal proportions. Preferably, the arsenic sulfide compound is

As₄S₄ and the pharmaceutically acceptable carrier is *seman platycladi*.

The present invention also provides a pharmaceutical composition useful for treating cancer, particularly hematological cancer including leukemia or lymphoma, in a mammal which comprises an effective amount of an arsenic sulfide compound, preferably with a pharmaceutically acceptable carrier or incipient, and further comprising an effective amount of an arsenious compound, wherein the arsenic sulfide compound and the arsenious compound are not the same compound. In a specific embodiment, the arsenious compound is selected from the group consisting of As₂S₂, As₂S₃, As₂S₄, As₄S₄ and As₂O₃. Preferably, the arsenic sulfide compound is As₄S₄.

Although § 5.4. discloses a process for producing As₄S₄, which is substantially free of As₂O₃, these two compounds can be used in combination. In fact, in one of the preferred embodiment, the present invention provides a pharmaceutical composition useful for treating cancer, particularly hematological cancer including leukemia or lymphoma, in a human which comprises an effective amount of As₄S₄, As₂O₃ and a pharmaceutically acceptable carrier; or in a method of treatment which employs both As₄S₄ and As₂O₃.

The present invention further provides a pharmaceutical composition useful for treating cancer, particularly hematological cancer including leukemia or lymphoma, in a human which comprises an effective amount of an arsenic sulfide compound, and preferably a pharmaceutically acceptable carrier or incipient, and further comprising an effective amount of a therapeutic agent including but is not limited to mustard compounds, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, busulfan, 6-mercaptopurine, 6-thioguanine, cytarabine, cytosine arabinoside, 5-fluorouracil, floxuridine, methotrexate, vincristine, vinblastine, taxol, etoposide, temiposide, dactinomycin, daunorubicin, doxorubicin, epirubicin, mitoxantron, bleomycin, mitomycin, cisplatin, carboplatin, estramustine

phosphate, hydroxyurea, BCNU, procarbazine, VM-26 (vumon), interferons and all-trans retinoic acid.

The present invention provides pharmaceutical composition useful for treating cancer, particularly hematological cancer including leukemia or lymphoma, in a human which comprises an effective amount of realgar and a pharmaceutically acceptable carrier or incipient.

According to the present invention, the arsenic sulfide compounds and their physiologically acceptable salts or solvates may be formulated for oral or parenteral administration.

For oral administration, the pharmaceutical preparation may also be in liquid form, for example, solutions, syrups or suspensions, or may be presented as a drug product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well-known in the art.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane,

dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water or other solvents, before use.

The invention also provides kits for carrying out the therapeutic regimens of the invention. Such kits comprise in one or more containers therapeutically effective amounts of the arsenic sulfide compounds in pharmaceutically acceptable form. The arsenic sulfide compound in a vial of a kit of the invention may be in the form of a pharmaceutically acceptable solution, e.g., in combination with sterile saline, dextrose solution, or buffered solution, or other pharmaceutically acceptable sterile fluid. Alternatively, the complex may be lyophilized or desiccated; in this instance, the kit optionally further comprises in a container a pharmaceutically acceptable solution (e.g., saline, dextrose solution, etc.), preferably sterile, to reconstitute the complex to form a solution for injection purposes.

In another embodiment, a kit of the invention further comprises a needle or syringe, preferably packaged in sterile form, for injecting the complex, and/or a packaged alcohol pad. Instructions are optionally included for administration

of arsenic sulfide compounds by a clinician or by the patient.

5 The magnitude of a therapeutic dose of an arsenic compound in the acute or chronic management of cancer, including leukemia or lymphoma, will vary with the severity of the condition to be treated and the route of administration. The dose, and perhaps dose frequency, will also vary according to the age, body weight, condition and response of the individual patient. For example, the total
10 daily dose ranges of arsenic disulfide for the conditions described herein are generally from about 100 mg to about 2 g administered in divided doses administered parenterally or orally or topically.

Desirable blood levels may be maintained by a continuous
15 infusion of an arsenic sulfide compound as ascertained by plasma levels. It should be noted that the attending physician would know how to and when to terminate, interrupt or adjust therapy to lower dosage due to toxicity, or bone marrow, liver or kidney dysfunctions. Conversely, the
20 attending physician would also know how to and when to adjust treatment to higher levels if the clinical response is not adequate (precluding toxic side effects).

Again, any suitable route of administration may be employed for providing the patient with an effective dosage
25 of an arsenic sulfide compound. For example, oral, transdermal, iontophoretic, parenteral (subcutaneous, intramuscular, intrathecal and the like) may be employed. Dosage forms include tablets, troches, cachet, dispersions, suspensions, solutions, capsules, patches, and the like.
30 (See, Remington's Pharmaceutical Sciences).

In practical use, an arsenic sulfide compound can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier or incipient according to conventional pharmaceutical compounding techniques. The
35 carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including tablets, capsules, powders, intravenous injections or infusions). In preparing the compositions for

oral dosage form any of the usual pharmaceutical media may be employed, e.g., water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like; in the case of oral liquid preparations, e.g., suspensions, solutions, elixirs, liposomes and aerosols; starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like in the case of oral solid preparations e.g., powders, capsules, and tablets. In preparing the compositions for parenteral dosage form, such as intravenous injection or infusion, similar pharmaceutical media may be employed, e.g., water, glycols, oils, buffers, sugar, preservatives, liposomes and the like known to those skilled in the art. Examples of such parenteral compositions include, but are not limited to Dextrose 5%w/v, normal saline or other solutions. The total dose of the arsenic sulfide compound may be administered in a vial of intravenous fluid, e.g., ranging from about 2 ml to about 2000 ml. The volume of dilution fluid will vary according to the total dose administered.

5.3. METHODS OF TREATMENT

The term "a method for treating cancer" as used herein means that the disease and the symptoms associated with the cancer are alleviated, reduced, ameliorated, prevented, placed in a state of remission, or maintained in a state of remission. For example, where the cancer to be treated is leukemia, the methods of treatment of the invention can lower the white blood cell count, or reduce lymphocytosis in a human under treatment.

In one embodiment, the present invention provides a method for treating cancer, particularly hematological cancer including leukemia or lymphoma, in a mammal comprising administering to said mammal, to which such treatment is needed, an effective amount of an arsenic sulfide compound and preferably a pharmaceutically acceptable carrier or incipient.

In another embodiment, the present invention provides a method for treating cancer, particularly hematological cancer

including leukemia or lymphoma, in a mammal comprising administering to said mammal, to which such treatment is needed, an effective amount of an arsenic sulfide compound, an arsenious compound, and preferably a pharmaceutically acceptable carrier or incipient, wherein the arsenic sulfide compound and the arsenious compound are not the same compound.

In still another embodiment, the present invention provides a method for treating cancer, particularly hematological cancer including leukemia or lymphoma, in a human comprising administering to said human, to which such treatment is needed, an effective amount of the pharmaceutical compositions disclosed in § 5.2.

Examples of hematological cancer that can be treated by the present methods include, but are not limited to, acute lymphoblastic leukemia (ALL), acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute nonlymphoblastic leukemia (ANLL), acute myeloblastic leukemia (AML), acute promyelocytic leukemia (APL), acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), multiple myeloma, myelodysplastic syndrome (MDS) such as refractory anemia with excessive blast (RAEB) and RAEB in transformation to leukemia (RAEB-T), and chronic myelo-monocytic leukemia (CMML). Preferably, the hematological cancer to be treated is acute promyelocytic leukemia (APL), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL) and multiple myeloma.

Examples of lymphoma that can be treated by the present methods include, but are not limited to, high grade lymphoma, intermediate grade lymphoma and low grade lymphoma. Preferably, the lymphoma to be treated is non-Hodgkin's lymphoma.

The skilled artisan will recognize that other cancers, particularly hematological cancers, may be treated in accordance with the present invention.

In a specific embodiment, the arsenic sulfide compound is selected from the group consisting of As_2S_2 , As_2S_3 , As_2S_5 and As_4S_4 . Preferably, the arsenic sulfide compound is As_4S_4 . More preferably, As_4S_4 is produced according to the methods disclosed in § 5.4. In another specific embodiment, the arsenious compound is selected from the group consisting of As_2S_2 , As_2S_3 , As_2S_5 , As_4S_4 and As_2O_3 . In a method wherein the arsenic sulfide compound being used is As_4S_4 , the arsenious compound, preferably, is As_2O_3 .

The present invention also provides a method for treating a human who is newly diagnosed of, or who is in relapsing stage of leukemia or lymphoma, preferably, acute promyelocytic leukemia (APL), chronic myelocytic leukemia (CML), non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) or multiple myeloma, which comprises: a) administering to said human an effective amount of an arsenic sulfide compound a number of times for a first period of time; and b) administering to said human an effective amount of an arsenic sulfide compound a reduced number of times for a second period of time, wherein the sum of the first period and second period does not exceed 100 days. In one specific embodiment, the arsenic sulfide compound, e.g., As_4S_4 , is administered 4 times daily for the first period of time. In another specific embodiment, the arsenic sulfide compound, e.g., As_4S_4 , is administered 3-4 times daily for the second period of time.

The present invention further provides a method for maintaining a human in complete remission stage of leukemia, preferably, acute promyelocytic leukemia (APL), chronic myelocytic leukemia (CML), non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) or multiple myeloma, which comprises: a) administering to a human who is in remission stage of said leukemia or lymphoma an effective amount of an arsenic sulfide compound for a first period of time; b) conducting clinical tests on said human for said leukemia or lymphoma; and c) administering to said patient an effective amount of an arsenic sulfide compound, if results of the clinical tests in step (b) indicate that the administration

is necessary to completely maintain the patient in remission stage of said leukemia or lymphoma. In one specific embodiment, the arsenic sulfide compound, e.g., As₂S₃, is administered 3-4 times daily for the first period of time. In another specific embodiment, the second period of time ranges from about 2 weeks to about years.

As used herein, "complete remission" is defined as having less than 5% blast cells and leukemic promyelocytes with normal blood pictures accompanied by no clinical manifestations of leukemia. Clinical and other tests for APL include, but are not limited to, the morphological feature of APL cells in blood and bone marrow, a chromosomal translocation, e.g., t(15;17), existence of PML/RAR α mRNA and other immunological markers that are indicative of APL.

In accordance with the present invention, arsenic sulfide compounds can be used alone or in combination with other known therapeutic agents (including chemotherapeutics, radioprotectants and radiotherapeutics) or techniques to either improve the quality of life of the patient, or to treat leukemia or lymphoma. For example, the arsenic sulfide compounds can be used before, during or after the administration of one or more known antitumor agents including but not limited to mustard compounds, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, busulfan, 6-mercaptopurine, 6-thioguanine, cytarabine, cytosine arabinoside, 5-fluorouracil, floxuridine, methotrexate, vincristine, vinblastine, taxol, etoposide, temiposide, dactinomycin, daunorubicin, doxorubicin, epirubicin, mitoxantron, bleomycin, mitomycin, cisplatin, carboplatin, estramustine phosphate, hydroxyurea, BCNU, procarbazine, VM-26 (vumcn), interferons and all-trans retinoic acid (ATRA), (See, for example, the Physician Desk References 1997). In addition, the arsenic sulfide compounds can be used before, during or after radiation treatment.

As used herein the terms "a therapeutic agent", "therapeutic regimen", "radioprotectant", "chemotherapeutic" mean conventional drugs and drug therapies, including vaccines, for treating cancer, viral infections, and other

malignancies, which are known to those skilled in the art.
"Radiotherapeutic" agents are well known in the art.

In a preferred embodiment, the arsenic sulfide compound of the invention is administered orally before, during or
5 after a patient undergoes other types of chemotherapy or radiotherapy.

5.4. PROCESSES FOR PRODUCING ARSENIC DISULFIDE

The present invention provides a process for producing
10 arsenic disulfide (As_2S_3), said As_2S_3 being substantially free of arsenic trioxide (As_2O_3), which comprises: (a) suspending realgar in an aqueous solution at pH about 6-7; (b) adjusting pH of the realgar suspension to pH about 4-4.5; (c) decanting resultant supernatant and resuspending the remaining sediment
15 in a solution at pH about 4-4.5; (d) repeating step (c) until arsenic concentration in said supernatant is less than 20 mg/L; (e) washing the remaining sediment from step (d) with an aqueous solution at pH about 6-7; and (f) drying said powder under non-oxidizing condition.

20 As used herein, "substantially free of arsenic trioxide (As_2O_3)" means that the content of As_2O_3 , on weight basis, is less than 0.15% in the produced As_2S_3 . Preferably, the content of As_2O_3 is less than 0.1%.

Realgar exists widely in the nature. For instances,
25 realgar has been found in Sb ores of Yugoslavia, in hot spring deposits in the former USSR, in borate deposits in Turkey, and in gold ores of Montana and Armenia (*Dictionary of Inorganic Compounds* (Ed. Macintyre et al., Chapman & Hall 1992) Vol. 1, p119). Realgar that exists naturally can be
30 used as the raw material for producing As_2S_3 in the present method.

In a specific embodiment, the aqueous solution that is used to suspend mined realgar and to wash the realgar sediment in steps (a) and (e) is deionized double distilled
35 water.

In another specific embodiment, the acidic solution that is used to adjusting pH and resuspending the realgar sediment in steps (b) and (c) is hydrochloric acid or acetic acid

solution. HCl and HAc can be used interchangeably during the process. Preferably, 0.1 M HCl solution or 0.1 M HAc solution is used.

5 The arsenic disulfide powder can be dried under non-oxidizing condition by the methods known in the art. Preferably, the arsenic disulfide powder is dried at low temperature.

The present invention also provides arsenic disulfide that is produced according to the above processes.

10

6. EXAMPLES

6.1 PRODUCING ARSENIC DISULFIDE SUBSTANTIALLY FREE OF ARSENIC TRIOXIDE

15 Realgar crystals were carefully, manually selected from mixed material sources by experienced personnel. Usually, only a very small amount of purified product can be produced from a large amount of unpurified realgar, which contains stones and toxic substances such as As_2O_3 , $(CaMg)_3(AsO_4)_2$ and $(CaMg)(AsO_4)_2$. In this example, the realgar ore contains >98% of As_2S_3 . The remaining of the realgar ore contains water and other impurities.

20 Stones were removed from the realgar ore. The resulting realgar crystal, weighed 50-100 g, was placed in a large mortar filled with 0.5 liter of deionized double-distilled water (DD water). The crystal was broken up, ground with a pestle and suspended in DD water. The pH of the suspension was adjusted to pH 4.5 by adding 0.12 M HCl. This grinding process continued for 2 hours either manually or in a mortar with motorized pestle. The sediment was allowed to settle, and the supernatant being left was decanted or siphoned. The above washing and grinding process was repeated three times, each for 2 hours, with HCl solution (pH 4.5). The fourth process was done in a big beaker with a magnetic stirrer overnight. The supernatant was decanted and tested for 35 arsenic with atomic absorption spectrophotometer. Arsenic in the supernatant should not exceed 20 mg/L. Otherwise, the above washing process with the magnetic stirrer in the beaker should be continued for additional 3-4 hours until arsenic

concentration in the supernatant was below 20 mg/L. The supernatant was discarded. The remaining arsenic disulfide sediment was washed with 1 liter DD water twice, each for two hours in a beaker with magnetic stirring. The remaining fine powder was dried at 4°C.

6.2 PRODUCING ARSENIC DISULFIDE FORMULATION

Seman platycladi, a plant semen, was used as a pharmaceutical carrier in formulating a arsenic-disulfide-containing composition that is suitable for oral administration. *Seman platycladi* was obtained from herb medicine market. 0.5 g of As_2S_3 , produced by the aforementioned method, was mixed and ground with 0.25 g of *seman platycladi*. The mixture was then placed into capsules resulting a total weight of 0.5 g per capsule. Such capsule is particularly useful in oral administration.

In other experiments, a number of solvents, such as polyvinylpyrrolidone, pyrrolidone, alcohol, ether, di-sodium hydrophosphate, mercaptopurine and sodium bicarbonate, were tested to increase solubility of As_2S_3 . As_2S_3 was shown to be soluble at various concentrations of the above solvents. Accordingly, As_2S_3 solubilized in the above solvents is useful for intravenous administration.

6.3 CLINICAL TREATMENTS

6.3.1 TREATMENT PROTOCOLS

Newly diagnosed, or relapsing patients are given a different protocol of treatment than are those patients who are in current remission. To induce complete remission, the patient is administered a measured dose of the arsenic disulfide-containing compound four times daily for three days. Preferably the dose given will range from approximately 0.5 to approximately 0.75 gram of arsenic disulfide. This equates to 2 to 3 capsules, according to the above formulation, by mouth for one dose. After the initial three days, the patient is given the compound three times daily until remission is induced. To prevent complications due to the potential build up of arsenic in the body,

treatment should not exceed 100 days. In most cases, favorable response should be induced before forty days of treatment. These later doses may be somewhat reduced in amount compared to the original three day dosages. If after 100 days of treatment the patient does not respond favorably, the treatment should be stopped. At this point, the patient should be reevaluated through testing, and allowed to rest before beginning another course of treatment according to the present protocol.

The protocol for maintaining patients in complete remission, or treating those in remission with residual genetic markers of leukemia differ from those outlined above. To maintain complete remission, the patient is given a measured amount, to be adjusted according to test results, of the compound containing arsenic disulfide three to four times daily for fourteen days. The patient then abstains from treatment for a set period of time. During this time, the patient is tested. Treatment is adjusted according to test results with the period of abstention lasting from two weeks to 100 days, depending upon results. The length of the maintenance procedure varies according to patients' conditions, and may last as long as 3 years (including treating and resting periods). Each dose during this phase of treatment preferably contains arsenic disulfide in the range of approximately 0.50 to 0.75 gram. Once again the preferred method of administration is orally through use of a capsule as described above. Usually, a maintenance treatment is divided into two stages.

6.3.2 CASE STUDIES

All patients who make up a part of the case studies have been diagnosed with APL on the basis of cell morphology of AML-M3, that is acute hypergranular promyelocytic leukemia, immunological cell markers, chromosomal analysis showing (15;17) translocation, and positive PML/RAR α mRNA expression. Some patients were referred to the study with a diagnosis based solely on pathologic changes in cell morphology; these patients' diagnoses were tracked and reconfirmed throughout

the study. Chronic myeloid leukemia and lymphoma patients have also benefitted from arsenic disulfide treatment, as illustrated by case studies 3 and 4.

5 Inclusion criteria for the study included patients in APL relapse, patients who are unable to attain complete remission with ATRA or cytotoxic agents, patients in complete remission after conventional treatment who show residual leukemic cells with PCR analysis, indicating likelihood of relapse. Fifty-one patients met the inclusion criteria for
10 the study.

Exclusion criteria for the study included history of hypersensitivity to arsenic compounds, previous treatment with arsenic-containing medications, patient in critical condition, excessively low or high white blood counts,
15 existing heart, liver or kidney conditions, and severe infection. Three patients were excluded on these grounds, leaving 48 patients in the study. All 48 cases were treated with arsenic disulfide according to the above protocol. ATRA or other cytotoxic agents were not used. All 48 patients are
20 living and Leukemia free as of April, 1998.

Ten of these patients were either newly diagnosed or in relapse (i.e. not in remission) before treatment according to the present protocol. Eight of these patients were given one course of treatment before attaining complete remission, the
25 remaining two patients took two and three courses of treatment each. All ten patients are alive and remain in complete remission, leukemia free.

Many patients in this study in complete remission before treatment showed positive results for markers indicating
30 residual leukemia cells. After treatment according to the maintenance protocol outlined above, all such patients turned out to be persistently negative when tested.

Side effects of treatment with arsenic disulfide are minimal when compared to those of other antineoplastic
35 agents. Potential side effects include loss of appetite, mild diarrhea, and transient reversible increase of aspartate aminotransferase (AST). A minority of patients experienced cutaneous itching or puffing of the eyelids, and mild

leukopenia occurred slowly in 34% of patients. One patient had thrombocytopenia without bleeding. There were no deaths associated with the use of arsenic sulfide.

5 CASE STUDY 1

A 35 year old male was diagnosed with APL on July 22, 1997, after noticing onset of symptoms the previous June. The patient had white blood cell counts of $7.0 \times 10^9/L$, hemoglobin 9 gm%, and platelet levels at $34.0 \times 10^9/L$.
10 Cytogenetic analysis showed the (15;17) translocation, and PCR showed PML-RAR α (+). One day of ATRA treatment was given to the patient prior to beginning arsenic disulfide treatment. The treatment per the above protocol began on July 22, 1997. Treatment was discontinued on August 19, 1997
15 after twenty-five days of treatment. On August 28, 1997, tests revealed the patient was in complete remission, having blast cells and leukemic promyelocytes less than 5%. This level was reached after only 36 days of treatment according to the protocol. As shown in Fig. 1, the patient saw a
20 marked increase in hemoglobin and platelet levels. Fig. 2 shows the dramatic decrease in blasts and white blood cells after the arsenic disulfide treatment was used.

CASE STUDY 2

25 A 32 year old female was diagnosed with APL on May 24, 1996. She was treated for 40 days with ATRA, and subsequently Harringtonin/Ara-C in four courses. The patient met some success, and had a rest period of six months. Patient relapsed on June 6, 1997. Her white blood cell count
30 was $2.2 \times 10^9/L$, hemoglobin 10.7 gm%, and platelet count $1.5 \times 10^9/L$. Treatment with arsenic disulfide began on July 9, 1997. The patient was treated according to protocol for 21 days. The patient went into complete remission on July 28, 1997. Fig. 3 shows that the patient saw a change in
35 hemoglobin and platelet levels. Fig. 4 shows the dramatic change in blasts and white blood cells after the arsenic disulfide treatment was used.

CASE STUDY 3

5 A 40 year old male was diagnosed as having chronic myeloid leukemia (CML) in February, 1959. At that time, he had a white blood cell count of $1.5 \times 10^5/\text{mm}^3$ and a platelet level of $1.4 \times 10^5/\text{mm}^3$. Initially, he was treated with Myleran. On January 20, 1960, the white blood cell count was $3.15 \times 10^6/\text{mm}^3$ showing a differential count of 11% promyelocyte and myelocyte. The bone marrow picture showed increased cellularity with a preponderance of myeloid series with 21% of myelocytes. Patient was given 0.6 gram of arsenic disulfide twice daily. While being treated, blood and bone marrow pictures were controlled. The patient died, on September 5, 1965 from infection unrelated to the arsenic sulfide treatment.

15

CASE STUDY 4

20 A 15 year old female diagnosed with non-Hodgkin's lymphoma in September 1996 was treated with a combination chemotherapy regimen and had cranial irradiation for meningeal lymphoma. She also had high dose chemo-radiotherapy for autologous stem cell transplant. The patient has several relapses including intracranial relapse and a large amount of lymphoma cells in peripheral blood with typical clinical and laboratory features of lymphoma/leukemia. She became resistant to conventional anti-cancer treatment. In March, 1998 she received arsenic disulfide treatment according to protocol. Since that time, she has been in remission.

25

30 The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

35

WHAT IS CLAIMED IS:

1. A pharmaceutical composition useful for treating hematological cancer in a mammal which comprises an effective amount of an arsenic sulfide compound.
2. The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier or excipient.
3. A pharmaceutical composition suitable for oral delivery to a human which comprises an effective amount of an arsenic sulfide compound.
4. The pharmaceutical composition of claim 3, further comprising a pharmaceutically acceptable carrier or excipient.
5. The pharmaceutical composition of claim 1, wherein said mammal is a human.
6. The pharmaceutical composition of claim 1, wherein the arsenic sulfide compound is selected from the group consisting of As_2S_2 , As_2S_3 , As_4S_6 , and As_4S_4 .
7. The pharmaceutical composition of claim 6, wherein the arsenic sulfide compound is As_4S_4 .
8. The pharmaceutical composition of claim 1, wherein the amount of said arsenic sulfide compound is from about 100 mg to about 2 g.
9. The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable carrier or excipient is a plant semen.
10. The pharmaceutical composition of claim 9, wherein the plant semen is *seman platycladi*.

11. The pharmaceutical composition of claim 1, further comprising an effective amount of an arsenious compound, wherein the arsenic sulfide compound and the arsenious compound are not the same compound.

12. The pharmaceutical composition of claim 11, wherein the arsenious compound is selected from the group consisting of As_2S_2 , As_2S_3 , As_2S_5 , As_4S_6 and As_2O_3 .

13. The pharmaceutical composition of claim 1, further comprising an effective amount of a therapeutic agent selected from the group consisting of mustard compounds, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, busulfan, 6-mercaptopurine, 6-thioguanine, cytarabine, cytosine arabinoside, 5-fluorouracil, floxuridine, methotrexate, vincristine, vinblastine, taxol, etoposide, temiposide, dactinomycin, daunorubicin, doxorubicin, epirubicin, mitoxantron, bleomycin, mitomycin, cisplatin, carboplatin, estramustine phosphate, hydroxyurea, BCNU, procarbazine, VM-26 (vumon), interferons and all-trans retinoic acid.

14. A pharmaceutical composition useful for treating hematological cancer in a mammal which comprises an effective amount of realgar and a pharmaceutically acceptable carrier or excipient.

15. A method for treating hematological cancer in a human comprising administering to said human, to which such treatment is needed, an effective amount of an arsenic sulfide compound.

16. The method of claim 15, further comprising a pharmaceutically acceptable carrier or excipient.

17. The method of claim 15, wherein said hematological cancer is selected from the group consisting of acute lymphoblastic leukemia (ALL), acute lymphoblastic B-cell

leukemia, acute lymphoblastic T-cell leukemia, acute
nonlymphoblastic leukemia (ANLL), acute myeloblastic leukemia
(AML), acute promyelocytic leukemia (APL), acute monoblastic
leukemia, acute erythroleukemic leukemia, acute
5 megakaryoblastic leukemia, chronic myelocytic leukemia (CML),
chronic lymphocytic leukemia (CLL), multiple myeloma,
myelodysplastic syndrome (MDS) such as refractory anemia with
excessive blast (RAEB) and RAEB in transformation to leukemia
(RAEB-T), and chronic myelo-monocytic leukemia (CMML).

10

18. The method of claim 17, wherein said hematological
cancer is acute promyelocytic leukemia (APL).

15

19. The method of claim 17, wherein said hematological
cancer is chronic myelocytic leukemia or chronic myeloid
leukemia (CML).

20

20. The method of claim 17, wherein said hematological
cancer is chronic lymphocytic leukemia (CLL).

21. The method of claim 17, wherein said hematological
cancer is multiple myeloma.

25

22. The method of claim 15, wherein said hematological
cancer is selected from the group consisting of high grade
lymphoma, intermediate grade lymphoma and low grade lymphoma.

30

23. The method of claim 15, wherein said hematological
cancer is non-Hodgkin's lymphoma.

35

24. The method of claim 15, wherein the arsenic sulfide
compound is selected from the group consisting of As_2S_2 , As_2S_3 ,
 As_2S_5 and As_4S_4 .

25. The method of claim 24, wherein the arsenic sulfide
compound is As_4S_4 .

26. The method of claim 15, wherein the amount of said arsenic sulfide compound is from about 100 mg to about 2 g.

5 27. A method for treating hematological cancer in a human comprising administering to said human, to which such treatment is needed, an effective amount of an arsenic sulfide compound and an arsenious compound, wherein the arsenic sulfide compound and the arsenious compound are not the same compound.

10

28. The method of claim 27, further comprising a pharmaceutically acceptable carrier or excipient.

15 29. The method of claim 27, wherein said hematological cancer is selected from the group consisting of acute lymphoblastic leukemia (ALL), acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute nonlymphoblastic leukemia (ANLL), acute myeloblastic leukemia (AML), acute promyelocytic leukemia (APL), acute monoblastic leukemia, acute erythroleukemic leukemia, acute
20 megakaryoblastic leukemia, chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), multiple myeloma, myelodysplastic syndrome (MDS) such as refractory anemia with excessive blast (RAEB) and RAEB in transformation to leukemia (RAEB-T), and chronic myelo-monocytic leukemia (CMML).
25

30. The method of claim 29, wherein said hematological cancer is acute promyelocytic leukemia (APL).

30 31. The method of claim 29, wherein said hematological cancer is chronic myelocytic leukemia or chronic myeloid leukemia (CML).

35 32. The method of claim 29, wherein said hematological cancer is chronic lymphocytic leukemia (CLL).

33. The method of claim 29, wherein said hematological cancer is multiple myeloma.

34. The method of claim 29, wherein said cancer is selected from the group consisting of high grade lymphoma, intermediate grade lymphoma and low grade lymphoma.

5 35. The method of claim 29, wherein said cancer is non-Hodgkin's lymphoma.

36. The method of claim 27, wherein the arsenic sulfide compound is selected from the group consisting of As_2S_2 , As_2S_3 , As_2S_5 , and As_4S_4 .

10 37. The method of claim 36, wherein the arsenic sulfide compound is As_4S_4 .

15 38. The method of claim 27, wherein the arsenious compound is selected from the group consisting of As_2S_2 , As_2S_3 , As_2S_5 , As_4S_4 , and As_2O_3 .

20 39. The method of claim 27, wherein the arsenic sulfide compound is As_4S_4 and the arsenious compound is As_2O_3 .

40. A method for treating a human who is newly diagnosed of, or who is in relapsing stage of leukemia or lymphoma which comprises:

- 25 a) administering to said human an effective amount of an arsenic sulfide compound a number of times for a first period of time; and
- b) administering to said human an effective amount of an arsenic sulfide compound a reduced number of times for a second period of time,

30 wherein the sum of the first period and second period does not exceed 100 days.

41. The method of claim 40, wherein the leukemia or lymphoma is selected from the group consisting of acute promyelocytic leukemia (APL), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma and multiple myeloma.

42. The method of claim 40, wherein the arsenic sulfide compound is As_2S_3 .

5 43. The method of claim 42, wherein the amount of As_2S_3 is from about 100 mg to about 2 g.

10 44. The method of claim 40, wherein the arsenic sulfide compound is administered 4 times daily for the first period of time.

45. The method of claim 40, wherein the arsenic sulfide compound is administered 3-4 times daily for the second period of time.

15 46. A method for maintaining a human in complete remission stage of leukemia or lymphoma which comprises:
a) administering to a human who is in remission stage of said leukemia or lymphoma an effective amount of an arsenic sulfide compound for a first period of
20 time;
b) conducting clinical tests on said human for said leukemia or lymphoma; and
c) administering to said patient an effective amount of an arsenic sulfide compound, if results of the
25 clinical tests in step (b) indicate that the administration is necessary to completely maintain the patient in remission stage of said leukemia or lymphoma.

30 47. The method of claim 46, wherein the leukemia or lymphoma is selected from the group consisting of acute promyelocytic leukemia (APL), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma and multiple myeloma.

35 48. The method of claim 46, wherein the arsenic sulfide compound is As_2S_3 .

49. The method of claim 46, wherein the amount of As_4S_4 is from about 100 mg to about 2 g.

50. The method of claim 46, wherein the arsenic sulfide compound is administered 3-4 times daily for the first period of time.

51. The method of claim 46, wherein the second period of time is from about 2 weeks to about 100 days.

52. A process for producing arsenic disulfide (As_2S_3), said As_2S_3 being substantially free of arsenic trioxide (As_2O_3), which comprises:

- (a) suspending realgar in an aqueous solution at pH about 6-7;
- (b) adjusting pH of the realgar suspension to pH about 4-4.5;
- (c) decanting resultant supernatant and resuspending the remaining sediment in a solution at pH about 4-4.5;
- (d) repeating step (c) until arsenic concentration in said supernatant is less than 20 mg/L;
- (e) washing the remaining sediment from step (d) with an aqueous solution at pH about 6-7; and
- (f) drying said powder under non-oxidizing condition.

53. The method of claim 52, wherein aqueous solution used in steps (a) and (e) is deionized double distilled water.

54. The method of claim 52, wherein the solution used in step (c) is hydrochloric acid or acetic acid solution.

55. The arsenic disulfide produced according to the method of claim 52.

Change of Hb and Plt. After As₄S₄ in

Case Study 1




Fig. 1

SUBSTITUTE SHEET (RULE 26)

Change of Blasts and WBCs After As₄S₄ in

Case Study 1




Fig. 2

SUBSTITUTE SHEET (RULE 26)

Printed from Mimosa

Change of Hb and Plt. After As₄S₄ in

Case Study 2




Fig. 3

SUBSTITUTE SHEET (RULE 26)

Change of Blasts and WBCs After As₄S₄ in

Case Study 2




Fig. 4

SUBSTITUTE SHEET (RULE 26)

Printed from Mimosa

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN 98/00118

A. CLASSIFICATION OF SUBJECT MATTER

IPC (6): A61K33/36

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched(classification system followed by classification symbols)

IPC (6): A61K33/36

Documentation searched other than minimum documentation to the extent that such documents are included in the field searched

Chinese Patent Applications Published or Announced Since 1985 and Chinese Non-Patent Documents

Electronic data base consulted during the international search(name of data base and, where practicable, search terms used)

WPI(Derwent), CNPAT(CN), JOPAL, CAPS(US), PCB(CN), MIMOSA(JP), ESPACC/ACCESS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant claim No.
X	Huang,shiling; Guo,aixia; Xiang, yang et al., "the Linic Study of QINGDAI tablet for Treating Acute Promyelocytic Leukemia", in "the China Magzine of Hematology", 1995,16(1), Page 26.	1-9,14
X	CN1061908A, 17.Jun.1992(17.06.92), the Obstetrical and Gynecological Hospital of Jiangxi, Page 3-5.	11-12
Y	CN 1121807A, 8.May.1996(08.05.96), the First Subsidiary Hospital of the Medical University of Haerbing, Page 1-4.	11-12
Y	Xiang,yang; Huang,shiling; Guo, aixia et al., "60 Cases of Treating Acute Promyelocytic Leukemia by QINGDAI tablet", in " the medical magzine of the Liberation Army ", 1995,20(3), Page 227-229.	13

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason(as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search
24.Jan.1999 (24.01.99)

Date of mailing of the international search report

28 JAN 1999 (28.01.99)

Name and mailing address of the ISA/
The Chinese Patent Office
6, Xitucheng Road, Haidian District,
Beijing, 100088, China

Authorized officer

Weibo, ZHANG

Facsimile No. 86-10-62019451

Telephone No. (86-010)62093734

Form PCT/ISA/210(second sheet)(July 1992)

Printed from Mimosa

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN 98/00118

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos: 15-51

because they relate to subject matter not required to be searched by this Authority, namely:

Claim 15-51 describes the treatment of diseases, they are not searched according to Rule 39.1(iv).

2. ☐ Claims Nos:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA /210 (continuation of first sheet (1)) (July 1998)